Literature DB >> 8425143

Life events and psychosis. Initial results from the Camberwell Collaborative Psychosis Study.

P Bebbington1, S Wilkins, P Jones, A Foerster, R Murray, B Toone, S Lewis.   

Abstract

Data from the Camberwell Collaborative Psychosis Study were used to examine the proposition that there is an excess of life events preceding the onset of psychoses of all types. Of 97 patients from the study who had episodes within the past year that were datable, 51 had developed psychotic symptoms from an essentially symptom-free state, 29 had been suffering only from neurotic symptoms, and 17 had experienced a marked exacerbation of psychotic symptoms. DSM-III diagnoses were collapsed into three major groups: 51 cases of schizophrenia; 31 cases of mania; and 14 cases of depressive psychosis. Life-event histories were taken for the six months before onset, and when these were compared with equivalent histories from a psychiatrically healthy sample from the local general population, there was a significant excess of life events, particularly in the three months before onset of psychosis. This was apparent in all groups, and remained even when events were restricted to the independent category. The excess of events began rather earlier than has been found in previous studies. In our view, this study provides some of the strongest evidence for a link between life events and the emergence of psychotic symptoms.

Entities:  

Mesh:

Year:  1993        PMID: 8425143     DOI: 10.1192/bjp.162.1.72

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  42 in total

1.  The public mental health significance of research on socio-economic factors in schizophrenia and major depression.

Authors:  Benedetto Saraceno; Itzhak Levav; Robert Kohn
Journal:  World Psychiatry       Date:  2005-10       Impact factor: 49.548

Review 2.  The neurobiology of social environmental risk for schizophrenia: an evolving research field.

Authors:  Ceren Akdeniz; Heike Tost; Andreas Meyer-Lindenberg
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2014-03-18       Impact factor: 4.328

3.  The early course of schizophrenia and depression*.

Authors:  Heinz Häfner; Kurt Maurer; Günter Trendler; Wolfram an der Heiden; Martin Schmidt
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-06       Impact factor: 5.270

4.  Exposure to Political Violence in Northern Ireland and Outcome of First Episode Psychosis.

Authors:  Aidan Turkington; Michael Duffy; Suzanne Barrett; Rosalind McCaul; Richard Anderson; Stephen J Cooper; Teresa Rushe; Ciaran Mulholland
Journal:  Schizophr Bull       Date:  2015-10-31       Impact factor: 9.306

5.  From stress to psychosis: whom, how, when and why?

Authors:  V Mondelli
Journal:  Epidemiol Psychiatr Sci       Date:  2014-06-06       Impact factor: 6.892

6.  Dopamine and spatial working memory in rats and monkeys: pharmacological reversal of stress-induced impairment.

Authors:  B L Murphy; A F Arnsten; J D Jentsch; R H Roth
Journal:  J Neurosci       Date:  1996-12-01       Impact factor: 6.167

7.  Insomnia, worry, anxiety and depression as predictors of the occurrence and persistence of paranoid thinking.

Authors:  Daniel Freeman; Daniel Stahl; Sally McManus; Howard Meltzer; Traolach Brugha; Nicola Wiles; Paul Bebbington
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2011-09-20       Impact factor: 4.328

Review 8.  Prevention of schizophrenia: can it be achieved?

Authors:  Cheng Lee; Thomas H McGlashan; Scott W Woods
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

9.  Prevalence of psychotic symptoms and their risk factors in urban Tanzania.

Authors:  Rachel Jenkins; Joseph Mbatia; Nicola Singleton; Bethany White
Journal:  Int J Environ Res Public Health       Date:  2010-06-10       Impact factor: 3.390

10.  Common mental disorders and risk factors in urban Tanzania.

Authors:  Rachel Jenkins; Joseph Mbatia; Nicola Singleton; Bethany White
Journal:  Int J Environ Res Public Health       Date:  2010-06-14       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.